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Because data from countries in Africa are limited, we 
measured the proportion of extensively drug-resistant (XDR) 
tuberculosis (TB) cases among TB patients in Burkina Faso 
for whom retreatment was failing. Of 34 patients with multi-
drug-resistant TB, 2 had an XDR TB strain. Second-line TB 
drugs should be strictly controlled to prevent further XDR 
TB increase.
E
xtensively drug-resistant (XDR) tuberculosis (TB) rep-
resents an emerging public health problem worldwide, 
characterized by alarming fatality rates regardless of pa-
tients’ HIV status (1,2). XDR TB is deﬁ  ned as in vitro re-
sistance to isoniazid and rifampin plus any ﬂ  uoroquinolone 
and at least 1 injectable drug (capreomycin, kanamycin, or 
amikacin).
Since 2006, a total of 49 countries have reported 
XDR TB (3). Data from countries in Africa are scant, with 
the exception of South Africa, where the prevalence is 
high, especially among HIV-infected persons (3). How-
ever, these data may reﬂ  ect diagnostic limitations rather 
than the true epidemiologic situation. In Burkina Faso, a 
low-income country in western Africa, TB prevalence is 
226 new cases per 100,000 population (4), and multidrug-
resistant (MDR) TB is estimated at 2.1% among new pa-
tients with smear-positive TB (5). During a systematic 
search for MDR TB among TB patients in Burkina Faso 
for whom a retreatment regimen was failing, we docu-
mented 2 cases of XDR TB.
The Study
In 2006, a program was established by the National Tu-
berculosis Program, Burkina Faso; the University of Brescia, 
Italy; and the San Raffaele Scientiﬁ  c Institute, Italy, to per-
form drug-susceptibility testing (DST) on sputum samples 
from patients listed in the Burkina Faso Chronic TB Reg-
ister. To be included in this register, patients must have ex-
perienced treatment failure after standard and retreatment 
regimens consisting of the following (in order): 2 months of 
streptomycin, rifampin, isoniazid, pyrazinamide, and etham-
butol; then 1 month of rifampin, isoniazid, pyrazinamide, 
and ethambutol; and then 5 months of rifampin, isoniazid, 
and ethambutol. Failure was deﬁ  ned as a persistently posi-
tive sputum smear after 5 months of treatment. All patients 
were informed and consented to the study.
From January 2006 through March 2009, a total of 156 
patients with chronic TB were registered in Burkina Faso. 
For 88 patients, sputum samples were collected before treat-
ment with second-line drugs; for 48, they were collected at 
1–12 months of treatment with second-line drugs. Samples 
were immediately frozen and stored at –20°C before being 
transferred on dry ice for culture and ﬁ  rst-line DST at the 
University of Brescia and for second-line DST and geno-
typing at San Raffaele Scientiﬁ  c Institute. Samples were 
cultured on an MGIT 960 automated system (Becton Dick-
inson Microbiology Systems, Cockeysville, MD, USA) ac-
cording to the manufacturer’s instructions. DST to ﬁ  rst- and 
second-line drugs was performed on all Mycobacterium tu-
berculosis isolates by classic dilution method.
M. tuberculosis was isolated from 50 samples; 45 pa-
tients had not yet taken second-line drugs and 5 had. Of the 
50 isolates, 34 (68%) were conﬁ  rmed as MDR TB, 29 from 
untreated patients and 5 from treated patients. We identi-
ﬁ  ed 2 cases of XDR TB (5.9% of all MDR TB cases): 1 
patient was sampled at month 24 of treatment with second-
line drugs, and 1 was initially classiﬁ  ed as having MDR TB 
before his disease progressed to XDR TB during follow-up 
treatment with second-line drugs.
Patient 1 was a 33-year-old man who was born in Côte 
d’Ivoire, moved to Burkina Faso in 2000, and received a di-
agnosis of smear-positive pulmonary TB in July 2003. He 
received an 8-month standard treatment regimen (including 
6 months of continuation with isoniazid and ethambutol). 
Treatment was directly observed during the ﬁ  rst 2 months. 
In January 2004, his treatment was classiﬁ  ed as failed, and 
he immediately started a standard retreatment regimen. Be-
cause his sputum did not clear by month 5, the patient was 
registered as a patient with chronic TB. During 2004, he 
traveled throughout Mali and Côte d’Ivoire. Back in Burki-
na Faso in January 2005, he was admitted to the reference 
national hospital for patients with chronic TB. His HIV test 
result was negative. At this time neither culture and DST 
nor a standard second-line drug regimen approved by the 
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Green Light Committee were available in Burkina Faso. 
The patient was empirically prescribed kanamycin, ethion-
amide, ciproﬂ  oxacin, and pyrazinamide, which he took un-
der direct observation as a hospital inpatient for 21 months; 
at discharge, his sputum samples remained positive.
In December 2006, 2 sputum samples showed resis-
tance to all ﬁ  rst-line drugs; resistance to second-line drugs 
amikacin, oﬂ   oxacin, ethionamide, and cycloserine; and 
susceptibility to para-aminosalicylic acid and capreomy-
cin. Appropriate and effective drugs were unavailable in 
the country. The patient was readmitted to the ward for 
patients with chronic TB and placed in a single isolation 
room. He died of TB in August 2008. Known contacts were 
monitored closely. A housemate was listed in the Chronic 
TB Register in June 2006. He traveled from Burkina Faso 
to Israel before DST could be performed. The patient’s 
sister-in-law died of MDR TB in March 2007; DST con-
ﬁ  rmed resistance to all ﬁ  rst-line drugs but susceptibility to 
amikacin and oﬂ  oxacin.
Patient 2 was a 44-year-old man. His MDR TB was di-
agnosed in Côte d’Ivoire in June 2007, and he immediately 
moved back to Burkina Faso to seek care. His HIV test 
result was negative. Sputum samples collected in July 2007 
grew MDR M. tuberculosis resistant to amikacin, kanami-
cin, ethionamide, and closerine but sensitive to ethambutol 
and oﬂ  oxacin. In September 2007, the patient started treat-
ment with Green Light Committee–approved second-line 
drugs (6 months of pyrazinamide, oﬂ  oxacine, kanamycin, 
ethionamide, and cycloserine followed by 15 months of 
oﬂ  oxacin, ethionamide, and cycloserine). Treatment was 
directly observed during the ﬁ  rst 13 months. His sputum 
samples remained positive throughout treatment, and ad-
ditional DST in October 2008 showed an XDR strain of 
M. tuberculosis. Mycobacterial interspersed repetitive unit 
genotyping showed an identical pattern for strains detected 
initially and during follow-up.
Conclusions
Our ﬁ  ndings conﬁ  rm that XDR TB can be found wher-
ever the search capacity exists. Thus, despite unavailability 
of evidence for the widespread existence of drug resistance, 
high priority should be given to strengthening laboratory 
capacities in sub-Saharan Africa (6). Also, because XDR 
TB developed while patient 2 was receiving second-line 
TB drugs, optimal adherence during intensive and continu-
ation phases of second-line treatment regimens should be 
ensured. Staff should receive speciﬁ  c training with regard 
to managing the frequent side effects.
Our study had 1 major limitation. Because our sam-
ple was a select population and included patients already 
receiving treatment with second-line drugs, we may have 
overestimated the proportion of XDR TB cases among 
MDR TB cases.
Mechanisms of emergence of XDR TB in Burkina 
Faso differ from those in South Africa, where most identi-
ﬁ  ed XDR TB cases are primarily resistant, occur among 
HIV-infected patients, and result from exposure in the hos-
pital or the community (7). Because each of the 2 XDR TB 
patients in Burkina Faso reported long-term stays in neigh-
boring countries, we believe that response to the MDR TB 
challenge should be based on regional rather than national 
strategies.
Our study supports current policies for strictly con-
trolled introduction of second-line drugs and the current 
Green Light Committee strategy that requires demonstra-
tion of compliance with guidelines for proper manage-
ment of MDR TB before granting access to second-line 
drugs (8). Stakeholders and TB program managers in Af-
rica should be reminded that the main reasons for devel-
opment of resistance in TB are poor patient adherence to 
treatment regimen, inappropriate drug prescription, irreg-
ular drug supply, and poor drug quality (9). When these 
factors occur with use of second-line TB drugs, the result 
will be XDR TB.
Rapid adoption of a programmatic approach to man-
agement of MDR TB (6) is warranted in Burkina Faso and 
probably other countries in western Africa. In countries 
without effective programs for community or outpatient 
care of patients with MDR TB, hospital care in reference 
centers enables appropriate follow-up during the initial 
phases of treatment. In this context, implementation of 
appropriate infection control measures should rank high 
among program priorities (10).
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